Erasca, Inc. (ERAS)
13.38
+0.51
(+3.96%)
USD |
NASDAQ |
Jun 09, 16:00
13.15
-0.23
(-1.72%)
After-Hours: 20:00
Erasca SG&A Expense (Quarterly) : 10.65M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 101.25M |
| Tango Therapeutics, Inc. | 15.24M |
| Kymera Therapeutics, Inc. | 20.36M |
| Bridgebio Oncology Therapeutics, Inc. | 6.377M |
| ImmunityBio, Inc. | 45.77M |